{"slideshow_credits": null, "snippet": "The latest uproar around Martin Shkreli has nothing to do with drug prices, but allegations of fraud at a small hedge fund.", "abstract": "Federal authorities' indictment of Turing Pharmaceuticals chief executive Martin Shkreli on securities fraud charges portrays his small-time fraud in hiding losses in his hedge funds; contend his Ponzi-like scheme involved looting his former company Retrophin to pay back upset investors.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Stephanie", "role": "reported", "lastname": "CLIFFORD", "rank": 1, "organization": ""}, {"firstname": "Matthew", "role": "reported", "lastname": "GOLDSTEIN", "rank": 2, "organization": ""}], "original": "By STEPHANIE CLIFFORD and MATTHEW GOLDSTEIN"}, "web_url": "http://www.nytimes.com/2015/12/18/business/dealbook/shkreli-indictment-portrays-small-time-fraud.html", "lead_paragraph": "The latest uproar around Martin Shkreli has nothing to do with drug prices, but allegations of fraud at a small hedge fund.", "headline": {"main": "Shkreli Indictment Portrays Small-Time Fraud ", "print_headline": "Shkreli Indictment Portrays Small-Time Fraud "}, "_id": "5673622538f0d85bed90f47b", "word_count": "1390", "multimedia": [{"height": 126, "url": "images/2015/12/18/business/18INDICT1/18INDICT1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/18/business/18INDICT1/18INDICT1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 527, "url": "images/2015/12/18/business/18INDICT1/18INDICT1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/18/business/18INDICT1/18INDICT1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "527"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/18/business/18INDICT1/18INDICT1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/18/business/18INDICT1/18INDICT1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Hedge Funds", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Retrophin Inc", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Securities and Commodities Violations", "is_major": "Y", "rank": "6"}, {"name": "organizations", "value": "MSMB Capital Management LLC", "is_major": "Y", "rank": "7"}, {"name": "subject", "value": "Ponzi and Pyramid Schemes", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}